Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01825577
Recruitment Status : Terminated (Administrative Reasons)
First Posted : April 5, 2013
Results First Posted : August 19, 2016
Last Update Posted : July 24, 2018
Sponsor:
Information provided by (Responsible Party):
St. Louis University

Brief Summary:

Falls in the elderly are a very common and serious health problem with devastating consequences. Those with dementia are 5 times more likely to experience falls than older people without significant cognitive impairment. Despite a growing awareness and the use of available treatments, the number of falls and fall related injuries continue to increase. It is important to develop more effective treatments to help reduce the number of falls and prevent injury. The assessments used in this study determine fall risk which predicts the likelihood of falls in the future.

This study will evaluate the possible role of Methylphenidate, Ritalin, in preventing falls and improving symptoms of apathy, or indifference. Methylphenidate is FDA approved for the treatment of ADHD but is not currently approved by the FDA for preventing falls or improving apathy(lack of interest) in the elderly. The methylphenidate used in this study will be absorbed through the skin by wearing a small patch near the hip area.

The specific primary aim of this open label study is to determine if use of transdermal Methylphenidate (t-MPH) causes a reduction in fall risk in patients with dementia.

The hypotheses to be tested is that after receiving t-MPH for 4 weeks, subjects will show improvement in gait and mobility assessment scores when compared to gait and mobility scores at screening.


Condition or disease Intervention/treatment Phase
Dementia Accidental Falls Apathy Drug: Transdermal Methylphenidate Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
Study Start Date : November 2012
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015


Arm Intervention/treatment
Experimental: Transdermal Methylphenidate
2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
Drug: Transdermal Methylphenidate
2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
Other Name: Daytrana




Primary Outcome Measures :
  1. Timed Get Up and Go Test - Measure of Mobility [ Time Frame: Baseline and Post-test at 4 weeks ]
    Timed Get Up and Go Test (TUG), is used to evaluate the ability to walk by measuring the time it takes to rise from a chair, walk 10 feet, turn around, walk back to the chair, and sit down. The TUG test takes less than 5 minutes to complete. Scored as seconds required to complete the task.


Secondary Outcome Measures :
  1. POMA -Performance Oriented Mobility Assessment - Measure of Gait and Balance. [ Time Frame: 4 weeks ]
    Performance Oriented Mobility Assessment (POMA), used to measure subject's ability to maintain balance. The test takes 10-15 minutes and involves asking subject to stand from a sitting position, standing with eyes closed and sitting down. POMA total score has a range of 0-36 where higher scores represent better performance. POMA total score is an additive combination of the 12 point Gait sub-score and the 16 point balance sub-score. A cut-off score of <21 is generally considered a fall risk among elderly people.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 95 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 65- 95 years of age
  2. Ability to ambulate (may use walking aid)
  3. Male or Female
  4. Clinical diagnosis of Dementia
  5. Identified as fall risk by nursing staff

Exclusion Criteria:

  1. Clinically significant musculoskeletal, cardiovascular or respiratory diseases.
  2. Clinically significant vestibular disorder
  3. History of significant head trauma
  4. Any medically unstable condition, as determined by the PI that would expose patient to potential harm.
  5. Patients taking medications that may interact with MPH, as determined by manufacture's package insert.

    Including but not limited to: Warfarin, anticonvulsants, MAOIs, alpha2-agonists, tri-cyclic antidepressants.

  6. Legally Blind
  7. History of seizures,
  8. Poorly controlled hypertension, cardiac arrhythmia or cardiovascular disease, heart failure.
  9. Known or suspected allergy to MPH or similar compounds
  10. Glaucoma
  11. Motor tics
  12. History of significant agitation or anxiety
  13. Family history of Tourette's syndrome
  14. History of significant anxiety
  15. History of significant agitation
  16. History of significant tension.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01825577


Locations
Layout table for location information
United States, Missouri
Delmar Gardens
Saint Louis, Missouri, United States, 63017
Sponsors and Collaborators
St. Louis University
Investigators
Layout table for investigator information
Principal Investigator: George T Grossberg, M.D. Saint Louis University School of Medicine Department of Neurology and Psychiatry
Principal Investigator: Ahmed A Baig, M.D. Saint Louis University School of Medicine Department of Neurology and Psychiatry

Layout table for additonal information
Responsible Party: St. Louis University
ClinicalTrials.gov Identifier: NCT01825577     History of Changes
Other Study ID Numbers: 23014
First Posted: April 5, 2013    Key Record Dates
Results First Posted: August 19, 2016
Last Update Posted: July 24, 2018
Last Verified: August 2016
Keywords provided by St. Louis University:
Alzheimer Dementia
Gait
Additional relevant MeSH terms:
Layout table for MeSH terms
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Methylphenidate
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents